Onconova Announces Presentation of Rigosertib Clinical Data in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting
November 07, 2013 09:36 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces Timing for Third Quarter 2013 Financial Results and Conference Call
November 05, 2013 18:04 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results
September 06, 2013 14:27 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
July 30, 2013 16:05 ET
|
Onconova Therapeutics
NEWTOWN, Pa., July 30, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) today announced the closing of its initial public offering of 5,941,667 shares of common stock at a public...